Equillium, INC 8-K filings

Equillium, Inc. announced its first quarter 2026 financial results, highlighting progress in its EQ504 program and a strengthened cash position.

Equillium, Inc. announced its fourth quarter and full year 2025 financial results, highlighting a strategic focus on EQ504 and securing financing to extend its operational runway into 2029.

Equillium, Inc. announced a private placement of common stock and pre-funded warrants to RA Capital Healthcare Fund, L.P., raising approximately $35.0 million to advance its EQ504 program and for general corporate purposes.

Equillium, Inc. announced third quarter 2025 financial results, a $30 million financing close, and plans to initiate a Phase 1 clinical study for its novel ulcerative colitis therapeutic, EQ504, in mid-2026.

Equillium, Inc. announced the formal engagement of Crowe LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2025.

Equillium, Inc. announced significant corporate governance changes, including auditor dismissal, director resignations, and the termination of a key collaboration agreement with Biocon, amidst a going concern warning.

Equillium, Inc. filed a prospectus supplement to increase its at-the-market equity offering program to up to $75 million.

Equillium, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, avoiding potential delisting.

Equillium, Inc. announced a private placement raising $30 million immediately with potential for an additional $20 million upon achieving key clinical and stock price milestones for its EQ504 program.

Equillium, Inc. announced a strategic shift to integrate a cryptocurrency treasury reserve strategy and reported $11.5 million in cash, sufficient to fund operations into Q4 2025, while seeking additional capital for its biotech pipeline.

Equillium, Inc. has been granted an additional 180 calendar days by Nasdaq, until December 8, 2025, to regain compliance with the minimum $1.00 bid price requirement, following a previous non-compliance notice.

Equillium, Inc. held its 2025 Annual Meeting of Stockholders where they approved an amendment to the 2018 Equity Incentive Plan and a reverse stock split.

Equillium announces disappointing FDA feedback regarding its itolizumab program for acute graft-versus-host disease, leading to a strategic reassessment and pipeline prioritization.

Equillium reports topline data from its Phase 3 EQUATOR study, highlighting statistically significant longer-term benefits of itolizumab in aGVHD despite not meeting the primary endpoint, and submits a request for Breakthrough Therapy designation to the FDA.

Equillium reports topline data from a Phase 2 study of itolizumab in ulcerative colitis, showing promising results compared to placebo and adalimumab.

Equillium, Inc. has been notified by Nasdaq that it is not in compliance with the minimum bid price requirement, as its stock price has fallen below $1.00 for 30 consecutive days.

Equillium, Inc. reports the resignation of a board member and the subsequent appointment of a new director and audit committee member.

Equillium announced its Q3 2024 financial results, highlighted the retention of itolizumab rights, and provided updates on its clinical programs, including the potential acceleration of the Phase 3 EQUATOR study.

Equillium has reprioritized itolizumab, paused enrollment in its EQUATOR study, and taken steps to extend its cash runway into Q4 2025.

Equillium, Inc. has regained compliance with Nasdaq's minimum bid price requirement after its stock price closed above $1.00 for ten consecutive business days.

Equillium announced positive second quarter 2024 financial results, highlighted by a $33.3 million cash balance and progress in clinical trials, with a key decision from Ono Pharmaceutical expected by the end of October regarding the acquisition of itolizumab rights.

Equillium, Inc. has been notified by Nasdaq that its stock price has fallen below the minimum bid price requirement, triggering a potential delisting process.

Equillium, Inc. has released a preliminary estimate of its cash, cash equivalents, and short-term investments, totaling approximately $33.3 million as of June 30, 2024.

Equillium's Phase 2 study of EQ101 in alopecia areata shows a favorable safety profile and improvements in hair loss, exceeding historical placebo response rates.

Equillium Inc. held its 2024 Annual Meeting, where stockholders approved a reverse stock split, elected three Class III directors, ratified the appointment of KPMG as auditor, and voted on executive compensation.

Equillium announced positive topline data from a Phase 1b study of itolizumab in lupus nephritis and reported a $32.3 million cash balance at the end of Q1 2024.

Equillium reports positive topline data from its Phase 1b EQUALISE study, showing significant reductions in urine protein in lupus nephritis patients treated with itolizumab.

Equillium announced its full year 2023 financial results, highlighting a $40.9 million cash balance and upcoming clinical data readouts for its key drug candidates.

Equillium, Inc. has appointed Penny Tom as its principal accounting officer, replacing Jason Keyes in that role, and has adopted a new inducement plan to grant equity awards to new employees.

Equillium Inc. has disclosed a preliminary cash balance of $40.9 million as of December 31, 2023, and filed a prospectus supplement for a potential $21.95 million share offering.